A Phase 1 interventional study of Daprodustat in Anaemia, sponsored by GlaxoSmithKline. Completed at 4 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 10 in phase 1, and was the 27th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 259 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 8th largest by enrollment, is one of 2 that started in 2020, is one of 14 in phase 1, and was the 34th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is comprised of two discrete Parts. Part A is a 3-period cross over evaluating relative bioavailability. Part B is a 2-period cross over evaluating bioequivalence. There will be a minimum of a 7-day washout period between treatment periods. Participants will participate in Part A or Part B, but not both. Approximately 200 participants will be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Daprodustat
Drug: Daprodustat
Drug: Daprodustat
Drug: Daprodustat
Drug: Daprodustat
Daprodustat will be available as oral tablets.
Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part B: AUC(0-t) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part B: Cmax Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part A: Apparent Clearance Following Oral Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part A: Apparent Volume of Distribution Following Oral Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Part B: AUC(0-inf) Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part B: Tmax Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part B: T1/2 Following Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part B: Apparent Clearance Following Oral Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Part B: Apparent Volume of Distribution Following Oral Administration of Daprodustat
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Participants were enrolled across 4 centers in the United States. This study consisted of two parts; Part A (3-period crossover study) and Part B (2-period crossover study).
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 18 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 15 | 16 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawn by sponsor due to impact of inclement weather events | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 15 | 16 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 15 | 16 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 15 | 16 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 5 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawn by sponsor due to impact of inclement weather events | 3 | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 21 | 19 | 21 | 22 | 21 | 21 | 21 | 21 | 20 | 20 |
| Completed | 0 | 0 | 0 | 20 | 19 | 20 | 20 | 21 | 19 | 21 | 20 | 20 | 20 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 20 | 19 | 20 | 20 | 21 | 19 | 21 | 20 | 20 | 20 |
| Completed | 0 | 0 | 0 | 20 | 19 | 20 | 20 | 21 | 19 | 21 | 20 | 20 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 20 | 19 | 20 | 20 | 21 | 19 | 21 | 20 | 20 | 20 |
| Completed | 0 | 0 | 0 | 20 | 19 | 20 | 20 | 21 | 19 | 21 | 20 | 19 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
| Hours*nanograms per milliliter | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat | 155.5 ± 14.7 | 159.9 ± 14.7 | 158.5 ± 14.7 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
| Hours*nanograms per milliliter | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: AUC(0-t) Following Administration of Daprodustat | 36.97 ± 13.5 | 38.02 ± 13.5 | 83.27 ± 17.0 | 79.08 ± 17.0 | 132.9 ± 15.4 | 134.2 ± 15.4 | 249.5 ± 16.3 | 241.5 ± 16.3 | 292.8 ± 16.3 | 278.5 ± 16.3 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
| Nanograms per milliliter | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat | 68.22 ± 28.7 | 71.06 ± 28.7 | 71.51 ± 28.7 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.
| Nanograms per milliliter | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: Cmax Following Administration of Daprodustat | 17.90 ± 22.2 | 17.39 ± 22.2 | 39.20 ± 28.8 | 35.30 ± 28.8 | 62.05 ± 30.9 | 60.21 ± 30.9 | 113.4 ± 26.7 | 109.7 ± 26.7 | 139.5 ± 27.6 | 120.0 ± 27.6 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours* nanograms per milliliter | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat | 159.9 ± 34.7 | 162.5 ± 31.5 | 161.5 ± 34.7 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat | 2.500 (0.500 to 8.00) | 2.000 (1.00 to 6.00) | 2.000 (1.00 to 4.00) |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat | 1.797 ± 28.9 | 1.910 ± 25.0 | 1.932 ± 34.0 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters per hour | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Apparent Clearance Following Oral Administration of Daprodustat | 25.02 ± 34.7 | 24.61 ± 31.5 | 24.77 ± 34.7 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 |
|---|---|---|---|
| Part A: Apparent Volume of Distribution Following Oral Administration of Daprodustat | 64.87 ± 42.4 | 67.81 ± 47.3 | 69.05 ± 50.9 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours* nanograms per milliliter | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: AUC(0-inf) Following Administration of Daprodustat | 37.71 ± 33.1 | 38.81 ± 37.8 | 84.36 ± 36.0 | 78.59 ± 34.1 | 135.5 ± 32.7 | 135.2 ± 33.0 | 250.4 ± 38.7 | 246.0 ± 40.5 | 295.8 ± 38.5 | 282.7 ± 39.3 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: Tmax Following Administration of Daprodustat | 2.000 (0.500 to 4.00) | 2.000 (0.517 to 4.00) | 2.250 (1.00 to 4.00) | 2.000 (0.500 to 4.00) | 2.000 (1.00 to 4.00) | 2.000 (0.500 to 4.00) | 2.000 (0.500 to 4.00) | 1.000 (0.500 to 4.00) | 2.000 (1.00 to 4.00) | 2.000 (0.500 to 6.00) |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hours | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: T1/2 Following Administration of Daprodustat | 1.162 ± 28.2 | 1.163 ± 30.2 | 1.545 ± 32.3 | 1.489 ± 32.6 | 1.814 ± 31.2 | 1.775 ± 26.5 | 1.852 ± 24.5 | 1.920 ± 24.4 | 1.997 ± 35.3 | 2.136 ± 35.0 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters per hour | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: Apparent Clearance Following Oral Administration of Daprodustat | 26.52 ± 33.1 | 25.76 ± 37.8 | 23.71 ± 36.0 | 25.45 ± 34.1 | 29.53 ± 32.7 | 29.58 ± 33.0 | 23.96 ± 38.7 | 24.39 ± 40.5 | 27.04 ± 38.5 | 28.30 ± 39.3 |
Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part B: Apparent Volume of Distribution Following Oral Administration of Daprodustat | 44.45 ± 31.7 | 43.22 ± 43.6 | 52.83 ± 43.1 | 54.65 ± 30.9 | 77.28 ± 43.9 | 75.74 ± 40.3 | 64.02 ± 37.1 | 67.56 ± 38.9 | 77.92 ± 54.5 | 87.21 ± 42.6 |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to 27 days in Part A and up to 18 days in Part B of the study.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Daprodustat Process 1 | 0/46 (0%) | 0/46 (0%) | 2/46 (4.3%) |
| Part A: Daprodustat Process 2 Dissolution Profile 1 | 0/45 (0%) | 0/45 (0%) | 3/45 (6.7%) |
| Part A: Daprodustat Process 2 Dissolution Profile 2 | 0/43 (0%) | 0/43 (0%) | 0/43 (0%) |
| Part B: Daprodustat 1 mg Process 1 | 0/39 (0%) | 0/39 (0%) | 1/39 (2.6%) |
| Part B: Daprodustat 1 mg Process 2 | 0/40 (0%) | 0/40 (0%) | 1/40 (2.5%) |
| Part B: Daprodustat 2 mg Process 1 | 0/42 (0%) | 0/42 (0%) | 3/42 (7.1%) |
| Part B: Daprodustat 2 mg Process 2 | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Part B: Daprodustat 4 mg Process 1 | 0/42 (0%) | 1/42 (2.4%) | 3/42 (7.1%) |
| Part B: Daprodustat 4 mg Process 2 | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Part B: Daprodustat 6 mg Process 1 | 0/42 (0%) | 0/42 (0%) | 6/42 (14.3%) |
| Part B: Daprodustat 6 mg Process 2 | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Part B: Daprodustat 8 mg Process 1 | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Part B: Daprodustat 8 mg Process 2 | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Event | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/46 | 0/45 | 0/43 | 0/39 | 0/40 | 0/42 | 0/41 | 1/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| Event | Part A: Daprodustat Process 1 | Part A: Daprodustat Process 2 Dissolution Profile 1 | Part A: Daprodustat Process 2 Dissolution Profile 2 | Part B: Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/46 | 0/45 | 0/43 | 0/39 | 0/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 2/40 | 0/40 |
| DizzinessNervous system disorders | 1/46 | 0/45 | 0/43 | 0/39 | 0/40 | 0/42 | 0/41 | 1/42 | 0/40 | 2/42 | 0/41 | 0/40 | 0/40 |
| HeadacheNervous system disorders | 0/46 | 0/45 | 0/43 | 0/39 | 0/40 | 2/42 | 1/41 | 1/42 | 1/40 | 0/42 | 1/41 | 1/40 | 0/40 |
| Back painMusculoskeletal and connective tissue disorders | 0/46 | 0/45 | 0/43 | 0/39 | 0/40 | 0/42 | 0/41 | 2/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| Feeling jitteryGeneral disorders | 0/46 | 0/45 | 0/43 | 1/39 | 0/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| FallInjury, poisoning and procedural complications | 0/46 | 0/45 | 0/43 | 0/39 | 1/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| Skin abrasionInjury, poisoning and procedural complications | 0/46 | 0/45 | 0/43 | 0/39 | 1/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| Blood pressure increasedInvestigations | 0/46 | 0/45 | 0/43 | 0/39 | 1/40 | 0/42 | 0/41 | 0/42 | 1/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| Soft tissue swellingMusculoskeletal and connective tissue disorders | 0/46 | 0/45 | 0/43 | 0/39 | 1/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
| TremorNervous system disorders | 0/46 | 0/45 | 0/43 | 0/39 | 1/40 | 0/42 | 0/41 | 0/42 | 0/40 | 0/42 | 0/41 | 0/40 | 0/40 |
Baseline Characteristics were presented for Safety Population.
| Age, Categorical(Participants) | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 18 | 18 | 21 | 19 | 21 | 22 | 21 | 21 | 21 | 21 | 20 | 20 | 259 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 8 | 8 | 7 | 11 | 10 | 4 | 8 | 6 | 4 | 5 | 4 | 86 |
| Male | 11 | 12 | 10 | 13 | 12 | 10 | 12 | 17 | 13 | 15 | 17 | 15 | 16 | 173 |
| Race/Ethnicity, Customized(Participants) | Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1 | Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2 | Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2 | Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1 | Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2 | Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1 | Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2 | Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1 | Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2 | Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1 | Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2 | Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1 | Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian - South East Asian Heritage | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 9 |
| Black or African American | 4 | 4 | 7 | 8 | 10 | 9 | 9 | 11 | 13 | 5 | 2 | 12 | 17 | 111 |
| Mixed Race | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| White - Arabic/ North African Heritage | 1 | 3 | 1 | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| White - White/ Caucasian/ European Heritage | 10 | 10 | 9 | 8 | 3 | 5 | 6 | 9 | 3 | 13 | 14 | 7 | 3 | 100 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Asian - Central/ South Asian Heritage | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Asian - East Asian Heritage | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 4 |
| Asian - Japanese Heritage | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 9 |
| Asian - Mixed Race | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Dec 2020 to primary completion in May 2021, 5 months.
Results were first posted in Jan 2023, 1 year 8 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 5 months is below that.
Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863